| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 interim results example | NGC-Cap Advanced or metastatic breast cancer | Phase 2 | — | Small Molecules | Oncology | ||
Phase 2 interim results example | NGC-Cap Advanced or metastatic breast cancer | Phase 2 | — | Small Molecules | Oncology | ||
Phase 2 interim results example | NGC-Cap Advanced or metastatic breast cancer | Phase 2 | — | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Processa Pharmaceuticals, Inc.$1.93
-0.09 (-4.46%)
D 22Pipeline Score Richly Valued Pharma · Clinical
Market Cap
7.29 M
EPS
-10.72
P/E Ratio
-
Value Trade
70.04 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
1.81 M
Operating CF
-3.59 M
Total Assets
4.52 M
Total Liabilities
1.98 M
Equity
2.54 M
D/E Ratio
12,345
-13.4 %
Week
-6.03 %
1 Month
15.22 %
3 Month
-62.53 %
6 Month
-99.92 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
1.69 M
Monthly Burn
1.20 M
Runway
0 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
32.77 K
52 Week Range
1.76 - 19.63
% held by Insiders
15.09 %
% held by Institutions
6.46 %
Enterprise Value
5.60 M
Total Shares
2.26 M
Short %
4.76 %
Float Shares
1.91 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D22
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.1x
rNPV / MCap Top 21%
Micro Cap (rank 716 of 905)
Percentile RankProcessa Pharmaceuticals, Inc. faces pipeline headwinds (22/100), with $302M risk-adjusted pipeline value, led by PCS499 in Necrobiosis Lipoidica (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCS499 Small molecule | Necrobiosis Lipoidica | Phase 2 | NCT03698864 | 14% | $97M | COMPLETED | 12 | - | - | Feb 25, 2020 | - | Oct 3, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PCS6422 | metastatic breast cancer | Phase 2 | 2025-07-02 | |||
PCS6422 | metastatic breast cancer | Phase 2 | 2025-07-02 | |||
PCS6422 | metastatic breast cancer | Phase 2 | 2025-07-02 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PCSA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
PCSA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PCSA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PCSA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PCSA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
PCSA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PCSAProcessa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
Processa Pharmaceuticals will attend the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026. CEO George Ng and Chief Business Officer Patrick Lin will hold one-on-one meetings to discuss their clinical pipeline, particularly the Phase 2 study of NGC-Cap for advanced breast cancer. Preliminary data indicate that NGC-Cap enhances exposure to effective metabolites while maintaining safety.
Read more →PCSAProcessa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
Processa Pharmaceuticals has completed the enrollment of 20 patients for a formal interim analysis in its Phase 2 study of NGC-Cap, a combination treatment for advanced breast cancer. This analysis aims to compare the safety and efficacy of NGC-Cap against standard capecitabine therapy. Results are anticipated in the first quarter of 2026, which will guide future study design and dose optimization.
Read more →PCSAProcessa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
Processa Pharmaceuticals provided an update on its Phase 2 study of NGC-Cap, a combination of PCS6422 and capecitabine for metastatic breast cancer. Preliminary data from 16 of 19 patients indicate that NGC-Cap enhances exposure to effective cancer-killing metabolites while maintaining a comparable safety profile to standard capecitabine therapy. The full interim analysis is expected in early 2026.
Read more →PCSAProcessa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
Processa Pharmaceuticals announced that its abstract for the adaptive Phase 2/3 study of PCS499 in patients with FSGS has been accepted for presentation at ASN Kidney Week 2025. The study aims to optimize dosing and address the urgent need for effective therapies in this rare kidney disease. PCS499 has demonstrated a favorable safety profile, potentially allowing for greater therapeutic benefits compared to existing treatments.
Read more →PCSAProcessa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
Processa Pharmaceuticals has announced a strategic investment and is exploring cryptocurrency treasury strategies to enhance financial flexibility and support its clinical development programs. The company aims to diversify its capital base while maintaining compliance with regulatory standards. CEO George Ng emphasized the commitment to delivering meaningful therapies for cancer patients and optimizing outcomes for shareholders.
Read more →PCSAProcessa Pharmaceuticals Provides Portfolio and Business Update
Processa Pharmaceuticals has provided an update on its product pipeline and business activities, emphasizing its focus on oncology assets with strong differentiation. The company is actively enrolling patients in its Phase 2 clinical trial for metastatic breast cancer and anticipates sharing initial data in the second half of 2025. CEO George Ng will discuss the strategic pipeline realignment in an upcoming investor webinar.
Read more →PCSAProcessa Pharmaceuticals Announces Pricing of $7 Million Public Offering
Processa Pharmaceuticals announced the pricing of a public offering of 28 million shares at $0.25 each, aiming to raise $7 million. The proceeds will be used to continue the Phase 2 clinical trial for NCG-Cap and for general corporate purposes. The offering is expected to close around June 18, 2025.
Read more →PCSAProcessa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
Processa Pharmaceuticals has signed a binding term sheet with Intact Therapeutics, granting them the exclusive option to license PCS12852, a promising treatment for gastroparesis. The agreement includes a $2.5 million option fee and potential milestone payments exceeding $452 million. PCS12852 has shown strong safety and efficacy in clinical trials, positioning it as a leading candidate for gastrointestinal motility disorders.
Read more →PCSAProcessa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
Processa Pharmaceuticals will participate in the 2025 BIO International Convention in Boston, where its leadership will meet with potential partners and investors. The focus will be on the company's Next Generation Cancer therapies, particularly NGC-Cap, which is currently in a Phase 2 trial for metastatic breast cancer. This event provides an opportunity to showcase their clinical advancements and regulatory science approach.
Read more →PCSAProcessa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
Processa Pharmaceuticals announced the acceptance of three abstracts for the 2025 ASCO Annual Meeting, showcasing their Next Generation Cancer drug candidates. The abstracts detail advancements in clinical and preclinical studies, including data on the safety and efficacy of NGC-Cap and the dose escalation of PCS11T. This reflects the company's commitment to addressing unmet needs in oncology.
Read more →PCSAProcessa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025
Processa Pharmaceuticals announced that Dr. David Young will present at the World Orphan Drug Congress USA 2025. His presentation will focus on applying FDA's Project Optimus principles to enhance drug efficacy and safety for rare diseases. This aligns with Processa's mission to develop next-generation cancer therapies.
Read more →PCSAProcessa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
Processa Pharmaceuticals will present at the MedInvest Biotech and Pharma Investor Conference on March 28, 2025. The company aims to showcase its innovative cancer therapies that enhance efficacy and safety. Management will also engage in one-on-one meetings with investors during the event. The presentation will be accessible on the company's website.
Read more →PCSAProcessa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
Processa Pharmaceuticals will present at the 2025 BIO CEO & Investor Conference on February 11, 2025. The company aims to showcase its innovative approach to developing next-generation cancer therapies that enhance safety and efficacy. Management will also hold one-on-one meetings with investors during the event, promoting further engagement and collaboration.
Read more →PCSAProcessa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Processa Pharmaceuticals has successfully closed a $5 million public offering priced at-the-market under Nasdaq rules. The offering included participation from the company's CEO, board members, and institutional investors. Gross proceeds are aimed at advancing their pipeline of next-generation chemotherapeutic drugs. The registration statement for the offering was declared effective by the SEC shortly before the closing date.
Read more →PCSAProcessa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Processa Pharmaceuticals has announced the pricing of a $5 million public offering, which includes 8,050,672 shares of common stock and accompanying Series A and B warrants. The offering is led by the company's CEO and various board members, with institutional investor involvement. The completion of the offering is subject to customary closing conditions and is expected to close by January 29, 2025. Additionally, the company will seek stockholder approval for the issuance of shares related to the warrants within 90 days post-offering.
Read more →PCSAProcessa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results
Processa Pharmaceuticals has marked significant progress by dosing the first patient in its Phase 2 clinical trial for NGC-Cap to treat metastatic breast cancer. The company reported positive data from preclinical studies for its NGC-Iri candidate, suggesting improved efficacy compared to existing therapies. However, the company has also faced financial challenges, with a net loss increasing to $3.4 million for Q3 2024 and reduced cash reserves. Processa remains focused on enhancing the safety and effectiveness of cancer treatments through its innovative drug development strategies.
Read more →PCSAProcessa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
Processa Pharmaceuticals has announced the dosing of the first patient in a Phase 2 clinical trial for NGC-Cap, targeting metastatic breast cancer. The trial aims to evaluate the safety and efficacy of NGC-Cap compared to capecitabine. With plans to activate around 30 clinical sites worldwide, this study could significantly advance treatment options in a field with a high need for improved therapies. Interim results are expected in mid-2025, building on positive findings from earlier trials.
Read more →PCSAProcessa Pharmaceuticals to Participate in Investor and Industry Conferences During September
Processa Pharmaceuticals, Inc. is set to participate in key investor and industry conferences in September 2024. The company will be attending the H.C. Wainwright 26th Annual Global Investment Conference and the European Society for Medical Oncology Congress. During these events, management plans to engage with investors, clinicians, and industry leaders to discuss their innovative oncology pipeline. This effort aims to bolster investor confidence and strengthen industry partnerships.
Read more →PCSAProcessa Pharmaceuticals Provides Product Pipeline and Financial Update
Processa Pharmaceuticals provided an update on its product pipeline and financial performance for the second quarter of 2024. The company has initiated a Phase 2 trial for its lead candidate NGC-Cap in metastatic breast cancer, following FDA clearance of its IND application. Positive results from preliminary trials indicate enhanced efficacy and safety, particularly with greater delivery of 5-FU to cancer cells. Additionally, the company reported a net loss of $3.0 million for the second quarter but maintains cash reserves of $5.6 million.
Read more →PCSAProcessa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
Processa Pharmaceuticals has announced positive findings from preclinical studies indicating that NGC-Iri may offer improved efficacy and a better safety profile over the current FDA-approved drugs irinotecan and Onivyde. In studies utilizing human melanoma xenograft mice, NGC-Iri demonstrated a higher accumulation of the active metabolite SN-38 in tumors while reducing its presence in non-cancerous tissues, suggesting fewer side effects. The company is currently working on defining the regulatory pathway for NGC-Iri as it aims to improve treatment options for cancer patients.
Read more →PCSAProcessa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
Processa Pharmaceuticals has received FDA clearance for its IND application, allowing the initiation of a Phase 2 clinical trial for NGC-Cap in patients with advanced or metastatic breast cancer. The trial aims to evaluate the safety and efficacy of NGC-Cap against standard monotherapy capecitabine. Expected to begin enrollment this quarter, initial data from the trial are anticipated by mid-2025, with hopes of offering a safer and more effective treatment option for breast cancer patients.
Read more →PCSAProcessa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer
Processa Pharmaceuticals has appointed Russell L. Skibsted as its new Chief Financial Officer, effective immediately. Skibsted has nearly three decades of experience in the pharmaceutical industry, having previously served as CFO at several notable biotech companies. He succeeds James Stanker, who is transitioning to an advisory role after his retirement. This leadership change is expected to aid Processa's progression in developing their pipeline of Next Generation Chemotherapy drugs.
Read more →PCSAProcessa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
Processa Pharmaceuticals announced positive efficacy results from its Phase 1b clinical trial of NGC-Cap in patients with advanced gastrointestinal cancer. In the trial, 66.7% of evaluable patients demonstrated progression-free survival ranging from 5 to 11 months, with all patients at the maximum tolerated dose showing notable responses. The treatment appeared to have a better side-effect profile compared to the standard monotherapy. The findings support the continuation of NGC-Cap development as a potential treatment for patients with this type of cancer.
Read more →PCSAProcessa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
Processa Pharmaceuticals, Inc. has announced its participation in the EF Hutton Annual Global Conference set for May 15, 2024, at The Plaza Hotel in New York City. The company will engage in one-on-one meetings with investors, highlighting its focus on developing advanced chemotherapy options with improved efficacy and safety. This engagement aims to enhance visibility among potential investors and stakeholders in the pharmaceutical sector.
Read more →PCSAProcessa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
Processa Pharmaceuticals has appointed Dr. Steven Cha as Senior Vice President of Clinical Research, a role intended to enhance its oncology drug development efforts. Dr. Cha, an experienced oncologist, will lead the clinical development of three ongoing oncology programs, beginning with a Phase 2 trial targeting breast cancer. His background includes successful drug approvals and extensive research in various cancer treatments, which may bolster Processa's capabilities in bringing effective therapies to market.
Read more →PCSAProcessa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial
Processa Pharmaceuticals presented two abstracts at the AACR Annual Meeting 2024, highlighting new data from its Phase 1b trial of NGC-Cap. The trial demonstrated that NGC-Cap offers improved 5-FU exposure to cancer cells with a favorable safety profile compared to standalone capecitabine. While some adverse events were noted, the ongoing positive patient responses support the transition to a Phase 2 trial for breast cancer. Final trial data will be released upon database lock, and regulatory paths are streamlined by prior interactions with the FDA.
Read more →PCSAProcessa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
Processa Pharmaceuticals, a clinical-stage pharmaceutical company, announced it will present two posters at the upcoming American Association for Cancer Research Annual Meeting in San Diego from April 5-10, 2024. The presentations will focus on their next-generation chemotherapy drugs, specifically showcasing trials aimed at increasing exposure while improving safety profiles. The company believes that its innovative approach could improve cancer treatment outcomes and increase the likelihood of FDA approvals.
Read more →PCSAProcessa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
Processa Pharmaceuticals, Inc. will present updates at the 2024 BIO CEO & Investor Conference on February 26-27, 2024, in New York City. CEO George Ng is set to provide insights on the company's next-generation chemotherapy drugs designed to enhance cancer treatment efficacy and safety. Processa focuses on modifying existing FDA-approved drugs to improve patient outcomes while reducing side effects. Investors will have the opportunity for one-on-one meetings with Mr. Ng during the conference.
Read more →PCSAProcessa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced that CEO George Ng will present a corporate update at the Winter Wrap-Up MicroCap Rodeo 2024 Virtual Conference scheduled from February 20 to 23, 2024. The company is focused on developing next-generation chemotherapeutic drugs that aim to enhance the efficacy and safety for cancer patients. Processa's approach integrates a regulatory science strategy to potentially increase the chances of FDA approval for its oncology pipeline. The presentation will offer investors an opportunity for one-on-one meetings with the CEO during the conference.
Read more →PCSAProcessa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
Processa Pharmaceuticals, Inc. has successfully regained compliance with Nasdaq's minimum bid price rule, having maintained a closing bid price of at least $1.00 for 10 consecutive business days. This compliance indicates the company's improved market standing. Processa is dedicated to developing novel chemotherapy drugs aimed at enhancing the treatment efficacy and reducing side effects for cancer patients. Their innovative approach to drug development blends proven active molecules with regulatory science, aiming for better therapy options and higher chances of FDA approval.
Read more →PCSAProcessa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
Processa Pharmaceuticals, Inc. has announced the successful closing of a $7.0 million public offering, which consisted of 1,555,555 shares of common stock and related warrants. The offering's closing took place on January 30, 2024, following the effectiveness of a registration statement by the SEC. Proceeds will be used to support the development of the company’s Next Generation Chemotherapy drugs aimed at improving treatment for cancer patients. This marks a significant financial milestone for the clinical-stage pharmaceutical company, enhancing its capacity to advance its oncology pipeline.
Read more →PCSAProcessa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
Processa Pharmaceuticals has announced the pricing of a public offering totaling $7.0 million, which includes 1,555,555 shares of common stock and accompanying common warrants. The offering is expected to close on or around January 30, 2024, pending customary closing conditions. This fundraising effort is part of the company's strategy to finance the development of its next-generation chemotherapy treatments aimed at enhancing cancer care for patients.
Read more →PCSAProcessa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
Processa Pharmaceuticals announced the successful completion of its Phase 1b trial for Next Generation Capecitabine (NGC-Cap), designed to improve cancer treatment safety and efficacy. The trial indicated that NGC-Cap was better tolerated than existing FDA-approved capecitabine, with reduced side effects and promising preliminary efficacy data. Two dosage regimens have been recommended for a Phase 2 trial in patients with advanced or metastatic breast cancer, following FDA endorsement. Overall, the trial results suggest a potential for NGC-Cap to provide a greater therapeutic window in cancer treatment.
Read more →PCSAProcessa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
Processa Pharmaceuticals has announced the expansion of its Next Generation Capecitabine (NGC-Cap) program to include treatment for advanced or metastatic breast cancer, following discussions with the FDA. The agency agreed that previous studies' data could be utilized for the upcoming Phase 2 trial, providing a more efficient path to potential approval. This strategic move is expected to address a larger market compared to prior indications and enhance the likelihood of success in clinical trials. The company plans to initiate the Phase 2 study in the third quarter of 2024, bolstering its development efforts with insights from breast cancer key opinion leaders.
Read more →PCSAProcessa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split
Processa Pharmaceuticals has announced a 1-for-20 reverse stock split following stockholder approval on November 14, 2023. This action, effective January 22, 2024, aims to help the company meet Nasdaq's minimum bid price requirement of $1.00 per share. After the split, the number of outstanding shares will decrease from approximately 24.6 million to 1.2 million, though the total value of shares owned by existing shareholders will remain unchanged, barring fractional shares. The company continues to focus on developing next-generation chemotherapy drugs intended to improve cancer treatment efficacy and safety.
Read more →PCSAProcessa Pharmaceuticals to Present at the Biotech Showcase 2024
Processa Pharmaceuticals, Inc. is set to present at the Biotech Showcase 2024, showcasing their focus on developing Next Generation Chemotherapy drugs aimed at improving cancer treatment outcomes. The presentation will take place on January 8, 2024, at the Hilton San Francisco Union Square, where CEO George Ng will provide a corporate overview. The company aims to enhance safety and efficacy in chemotherapy treatments through innovative approaches and a history of successful FDA approvals. Management will also hold one-on-one meetings with interested parties during the event.
Read more →PCSAProcessa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
Processa Pharmaceuticals announced positive interim analysis results from its ongoing Phase 1b trial of Next Generation Capecitabine (NGC-Cap). The data reveal that NGC-Cap can provide improved safety with higher 5-FU exposure and at much lower doses than traditional capecitabine. Additionally, the FDA has recognized NGC-Cap as a New Chemical Entity, which may confer commercial advantages. The company is also preparing for a Phase 2 trial based on these encouraging findings, scheduled for discussion in an upcoming Fireside Chat.
Read more →PCSAProcessa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine
Processa Pharmaceuticals announced a successful meeting with the FDA concerning its Phase 2 study for Next Generation Capecitabine (NGC-Cap). The FDA provided valuable guidance on the study design, enhancing the company's strategy moving forward. Processa anticipates beginning trial enrollment in mid-2024, with interim Phase 1b results expected to support their efforts. NGC-Cap aims to improve safety and efficacy profiles for cancer patients, particularly those unable to tolerate current treatments.
Read more →PCSAProcessa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
Processa Pharmaceuticals, a clinical-stage biopharma company, will present at the MedInvest Oncology Investor Conference on December 5, 2023. Dr. David Young, the President of Research and Development, is scheduled to present virtually, while CEO George Ng will be available for in-person meetings with investors. The company focuses on developing next-generation chemotherapy drugs that aim to enhance the efficacy and safety for cancer patients. With three products currently in the pipeline, Processa is positioned to make significant advancements in cancer treatment.
Read more →PCSAProcessa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook
Processa Pharmaceuticals has issued an update letter to shareholders detailing its strategic focus on developing Next Generation Chemotherapy (NGC) drugs aimed at improving cancer treatment safety and efficacy. New CEO George Ng affirmed the company's commitment to oncology drug product development while leveraging a strong internal team with extensive regulatory experience. The pipeline consists of three NGC candidates, with planned clinical trials and cooperation with the FDA expected to enhance market presence. Despite financial challenges, Processa is optimistic about its prospects and aims to disrupt the chemotherapy market.
Read more →PCSAProcessa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson
Processa Pharmaceuticals, Inc. announced the unexpected passing of Virgil Thompson, a founding board member, on November 9, 2023. Mr. Thompson, who was 83 years old, served on the Board since the company's formation in 2017. His contributions to the company and the larger biotechnology field were acknowledged by Chairman Justin Yorke, who expressed gratitude for Thompson's leadership and guidance. The loss is likely to be felt throughout the organization as they continue their focus on developing innovative chemotherapy drugs.
Read more →PCSAProcessa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson Hanover, MD. (Global Newswire) - Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced today with great sadness that Virgil Thomp
Processa Pharmaceuticals, Inc. announced the unexpected passing of board member Virgil Thompson on November 9, 2023. Thompson, a founding board member since the company's inception in 2017, was 83 years old. The company expressed deep sadness and gratitude for his contributions, highlighting the impact of his leadership and wisdom on the Board and the organization as a whole. Processa Pharmaceuticals focuses on developing advanced chemotherapy drugs aimed at improving cancer treatment efficacy and safety.
Read more →PCSAProcessa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas
Processa Pharmaceuticals, Inc. will have a presentation at the 20th Orphan Drugs and Rare Diseases Global Congress on November 16-17, 2023. Dr. David Young, the President of Research and Development, will showcase the company’s developments in next-generation chemotherapy drugs aimed at improving efficacy and safety for cancer patients. The conference takes place at the Revere Hotel Boston Common and includes opportunities for one-on-one meetings, which could enhance collaboration in the oncology field. Processa's innovative approach may lead to better therapy options for patients through modifications of existing drugs.
Read more →PCSAProcessa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders
Processa Pharmaceuticals has announced the formation of an Oncology Advisory Board comprising recognized key opinion leaders in cancer research. This initiative aims to leverage their expertise in the design of trial protocols, specifically to enhance the anticipated Phase 2 trial for its novel oncology drug NGC-Cap. The advisory board is expected to facilitate improved safety and efficacy in cancer treatments, benefiting patient care and expanding treatment options. Processa's focus on next-generation chemotherapy aims to optimize therapeutic outcomes for cancer patients.
Read more →PCSAProcessa Pharmaceuticals to Present at the ThinkEquity Conference
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) will have its CEO George Ng present an updated corporate overview at the ThinkEquity Conference on October 19, 2023, in New York. The company is engaged in developing next-generation chemotherapy drugs aimed at enhancing treatment efficacy and safety for cancer patients. These modifications utilize proven active molecules with a focus on improving patient outcomes and increasing the likelihood of FDA approvals. A live webcast of the presentation will also be available for interested stakeholders.
Read more →PCSAProcessa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Processa Pharmaceuticals, Inc. will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference held from September 11 to 13, 2023. CEO George Ng and CFO James Stanker will be available for one-on-one meetings during the conference. The company is focused on developing next-generation chemotherapy drugs aimed at improving treatment efficacy and safety for cancer patients. This pipeline includes three novel drugs designed to modify existing FDA-approved oncology drugs.
Read more →PCSAProcessa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care
Processa Pharmaceuticals announced interim results from its Phase 1B trial of Next Generation Capecitabine (NGC-Cap) for gastrointestinal cancer patients. The data indicates that individualizing dosing regimens through monitoring DPD and FBAL levels can enhance treatment efficacy and safety, minimizing common chemotherapy side effects. Currently, the study has enrolled three out of five cohorts, with expected assessments of safety and efficacy by the year's end, paving the way for a potential Phase 2 trial.
Read more →PCSAProcessa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference
Processa Pharmaceuticals, Inc. is set to present a corporate overview at the Sidoti & Co. Micro Cap Virtual Conference on August 17, 2023. The presentation will be led by David Young, President of Research and Development, along with the newly appointed CEO, George Ng, who will also engage in one-on-one meetings with investors during the event. Processa is focusing on developing innovative chemotherapy drugs aimed at enhancing efficacy and safety for cancer patients, building on over 30 years of drug development expertise. The company’s approach integrates proven oncological molecules and regulatory strategies targeting FDA approval.
Read more →PCSAProcessa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer
Processa Pharmaceuticals has appointed George Ng as CEO, effective August 8, 2023. Ng brings significant experience from his previous roles in biotechnology, including leadership positions at Calidi Biotherapeutics and Scilex Pharmaceuticals. This leadership change aligns with Processa's strategic shift to focusing on Next Generation Chemotherapy, with intentions to enhance treatment efficacy for cancer patients. Dr. David Young will now concentrate solely on drug development within the company.
Read more →PCSAProcessa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress
Processa Pharmaceuticals is participating in the World Orphan Drug Congress, where CEO David Young will be involved in a panel discussion on best practices for drug development. Additionally, he will present on applying the FDA’s Project Optimus to enhance the development of next-generation chemotherapy drugs. The company aims to improve cancer treatment safety and efficacy. With a focus on innovative drug development, Processa seeks to engage with potential partners during the conference.
Read more →PCSAProcessa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative
Processa Pharmaceuticals has announced the initiation of a Phase 2 trial for its Next Generation Chemotherapy-Capecitabine (NGC-Cap) following guidance from the FDA. The trial aims to assess the safety and efficacy of NGC-Cap, which combines PCS6422 and capecitabine, in colorectal cancer patients. The company expects that these treatments will decrease side effects typically associated with cancer therapies while enhancing the response rates among patients. This development is in alignment with the FDA's Project Optimus Oncology Initiative.
Read more →PCSAProcessa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting
Processa Pharmaceuticals will present data on PCS12852 at the Digestive Disease Week 2023, showcasing its efficacy and safety in treating gastroparesis patients. The medication has improved patient symptom scores and gastric emptying rates, and the company is preparing to advance to a Phase 2b trial. Notably, this is seen as a significant milestone, especially given the safety concerns associated with existing FDA-approved gastroparesis therapies. The oral presentation will take place on May 6, 2023, at the event in Chicago.
Read more →PCSAProcessa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results
Processa Pharmaceuticals announced an update focusing on their Next Generation Chemotherapy drugs alongside financial results for the year 2022. The company successfully completed a Phase 2A trial of PCS12852, positioning it for potential business development. They aim to initiate a Phase 2B trial for Next Generation Capecitabine, which proposes to reduce side effects associated with conventional chemotherapy. However, their net loss increased substantially due to various factors including a non-cash impairment of an intangible asset, despite raising funds to support operational plans into 2024.
Read more →PCSAProcessa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST
Processa Pharmaceuticals, Inc. announced a conference call scheduled for March 30, 2023, at 4:30 p.m. EST to discuss its 2022 year-end results and provide updates on its drug development pipeline. The company focuses on developing Next Generation Chemotherapies to improve safety and efficacy compared to existing treatments. Processa's approach aims to enhance the probability of FDA approval and offers better treatment options for cancer patients. The call will be accessible via a live webcast and phone dial-in.
Read more →PCSAProcessa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine
Processa Pharmaceuticals has announced the dosing of the first patient in its 300 mg dose group for Next Generation Chemotherapy-Capecitabine. This trial aims to gather critical data on the drug's exposure versus adverse events, a requirement for FDA approval. Notably, patients have reported no hand-foot syndrome or cardiotoxicity, which are common side effects of current capecitabine treatments. Company officials anticipate guidance from the FDA on the Phase 2B trial design in mid-April 2023.
Read more →PCSAProcessa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
Processa Pharmaceuticals, Inc. announced that its President & CEO, Dr. David Young, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023. This presentation will cover the company's advancements in its Next Generation Chemotherapy drugs designed to have better safety-efficacy profiles than existing FDA-approved treatments. Interested parties can access a live webcast of the presentation on Processa's website. The event also provides an opportunity for 1X1 meetings with management for investors and stakeholders.
Read more →PCSAProcessa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies
Processa Pharmaceuticals has announced a strategic prioritization of its pipeline focusing on Next Generation Chemotherapies (NGCs), which are modified forms of existing FDA-approved cancer treatments intended to enhance safety and effectiveness. By altering the metabolism and distribution of these drugs, Processa aims to provide therapy options that could significantly improve patient outcomes. The company plans to hold FDA meetings to discuss the development of NGCs, including Phase 2B trials, furthering its commitment to innovative oncology solutions. In addition, Processa continues to evaluate options for monetizing other non-oncology assets as it aligns resources toward NGCs.
Read more →PCSAProcessa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules
Processa Pharmaceuticals, Inc. has announced the closure of a $6.25 million registered direct offering of 7,812,544 common shares priced at $0.80 each. The offering, which included both retail investors and insiders, will provide funding for future clinical trials, research and development, and general corporate purposes. The shares are issued under a shelf registration statement previously filed with the SEC. This financial move represents a significant step in supporting the company's initiatives for next-generation chemotherapy treatments.
Read more →PCSAProcessa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
Processa Pharmaceuticals, Inc. has announced a registered direct offering priced at $0.80 per share, resulting in expected gross proceeds of $6.25 million. The offering involves the sale of 7,812,544 common shares and is anticipated to close around February 14, 2023. Proceeds from this offering will be allocated towards future clinical trials, research and development, and general corporate purposes.
Read more →PCSAProcessa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules HANOVER, MD.
Processa Pharmaceuticals, Inc. announced a registered direct offering, raising $6.25 million by selling 7,812,544 common shares at $0.80 each. The offering is set to close around February 14, 2023, subject to customary conditions. The funds will be utilized for clinical trials, research and development, and working capital. This financial boost aims to advance their focus on next-generation chemotherapy drugs for patients with unmet medical needs.
Read more →PCSAProcessa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.
Processa Pharmaceuticals will present an update on its therapeutic strategies at the Biotech Showcase on January 11, 2023. CEO Dr. David Young will highlight the company’s future focus and ongoing development programs. Additionally, the management team will be available for one-on-one meetings with potential investors during the J.P. Morgan Healthcare Conference week. Processa aims to improve treatment options for patients with unmet medical needs through a regulatory science approach.
Read more →PCSAProcessa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial
A 0.5 mg daily dose of PCS12852 administered over 28 days in gastroparesis patients successfully improved gastroparesis symptoms in a clinically meaningful way as defined by greater than a 0.5 reduction in the ANMS GCSI-DD score compared to baseline. The percentage of patients w
Read more →PCSAProcessa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update
PCS12852 successfully demonstrates a positive effect on the gastric emptying rate, clearing the path for a Phase 2B trial in 2023. Next Generation Capecitabine (a combination of PCS6422 and capecitabine) successfully identifies dosing regimens for a Phase 2B trial to be initiate
Read more →PCSAProcessa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST
HANOVER, MD, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it wil
Read more →PCSAProcessa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial
Next Generation Capecitabine (NGC) Dosage Regimens Have Been Identified In The Ongoing Phase 1B Trial With Potentially Better Safety And Efficacy Profiles Than Existing Chemotherapy These NGC dosage regimens are significantly more potent than existing FDA-approved capecitabine t
Read more →PCSAProcessa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs
PCS12852 for Gastroparesis concluded enrollment a month ahead of schedule. Statistics on gastric emptying, safety and GEBT data will be available by the end of October and full topline data is expected before year end. New site added for PCS6422 to accelerate enrollment, importa
Read more →PCSAProcessa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022
HANOVER, MD, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition today announced that
Read more →PCSAProcessa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Board
Board Appointments Designed to Position Company for Anticipated Milestones While Ensuring Adherence to the Highest Governance Standards HANOVER, MD, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company using
Read more →PCSAProcessa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update
PCS12852 on target to complete enrollment by September Expanded efforts to increase enrollment in PCS499 and PCS6422 showing results HANOVER, Md., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage com
Read more →PCSAProcessa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST
HANOVER, MD, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it wil
Read more →PCSAProcessa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499
HANOVER, MD, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need cond
Read more →PCSAProcessa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022
HANOVER, MD., July 12, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have unmet medical conditions a
Read more →PCSAProcessa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
Amended Next Generation Capecitabine study has restarted which will elucidate timelines for de novo formation of DPD Expanded efforts for enrollment in PCS499 PCS12852 on target to complete enrollment by Q3 HANOVER, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceutical
Read more →PCSAProcessa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST
HANOVER, MD, May 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will
Read more →PCSAProcessa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)
Processa focuses on identifying the PCS6422 regimens to increase capecitabine potency while identifying the MTD of Next Generation Capecitabine The amended protocol will provide a more precise timeline of DPD inhibition and de novo formation while also supplying preliminary data
Read more →PCSAProcessa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis
Study will advance understanding of proper dosing while providing data to assist in the design of the next study for this >$1B market Expect top line data at the end of 2022 HANOVER, MD, April 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Process
Read more →PCSAProcessa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update
Targeting Major Milestones 2022 HANOVER, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment op
Read more →PCSAProcessa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST
HANOVER, MD, March 23, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it wi
Read more →PCSAProcessa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference
HANOVER, MD, March 10, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need con
Read more →PCSAProcessa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
HANOVER, MD., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survi
Read more →PCSAProcessa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Update
Clinical Drug Pipeline is Funded and Targeting Major Milestones mid-2022 HANOVER, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical con
Read more →PCSAProcessa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DPD in Phase 1b Interim Analysis
Next Generation Capecitabine inhibited DPD activity 24-48 hours after PCS6422 administration with < 10% of 5-FU metabolized to FBAL compared to 80% reported for FDA approved capecitabine. 24-48 hours after PCS6422 administration, 5-FU potency based on systemic exposure per mg of
Read more →PCSAProcessa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. EST
HANOVER, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, to
Read more →PCSAProcessa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis
HANOVER, MD, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, an
Read more →PCSAProcessa Pharmaceuticals to Participate in Upcoming Investor Conferences - Update
HANOVER, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, a
Read more →PCSAProcessa Pharmaceuticals to Present at the World Orphan Drug Congress USA, August 25-27
HANOVER, MD, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition today announced it wil
Read more →PCSAProcessa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
Adds fourth clinical asset, RX-3117, and targets major milestones in the second half of 2021 HANOVER, Md., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing drugs to improve the survival and/or
Read more →PCSAProcessa Pharmaceuticals Schedules Conference Call to Discuss Second Quarter Results and Provide Drug Development Update on August 12 at 5:30 p.m. EST
HANOVER, Md., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it wi
Read more →PCSAProcessa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer
Processa’s Phase 1b open label, multicenter trial is currently enrolling patients who have advanced, relapsed GI cancer that are refractory or intolerant to other therapies and are candidates for fluoropyrimidine monotherapy. HANOVER, MD., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Proce
Read more →PCSAProcessa Pharmaceuticals to Present at “Zooming with LD Micro” Virtual Investor Event on July 29, 2021 at 12:00 p.m. ET
HANOVER, MD, July 27, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it will be presenting at the upcoming “Zooming with LD Micro” virtual investor event on Thursday, July 29th, 2021 at 12:00 PM ET. Investors and other individuals may
Read more →PCSAProcessa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET
HANOVER, MD, July 06, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that the company will present at Access to Giving Virtual Conference. The presentation will be given by Processa’s Chief Executive Officer, Dr. David Young. Registration
Read more →PCSAPROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117 HANOVER, MD
PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development MD - June 17, 2021 - Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP) to licen
Read more →PCSAPROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117
HANOVER, MD, June 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP) to license in RX-3117. RX-3117 is an oral, anticancer agent with an improved pharm
Read more →PCSAProcessa Set to Join Russell Microcap Index
HANOVER, MD, June 08, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, is
Read more →PCSAProcessa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET
HANOVER, MD, June 07, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, an
Read more →PCSAProcessa Pharmaceuticals to Participate in Upcoming Investor Conferences
HANOVER, MD, May 26, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, ann
Read more →PCSAProcessa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
~Processa’s trial is currently enrolling patients with ulcerated Necrobiosis Lipoidica. Detailed information on the trial can be located on clinicaltrials.gov NCT#: 04800562.~ HANOVER, MD., May 20, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Process
Read more →PCSAProcessa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
Clinical drug pipeline is funded and targeting major milestones in Q2 and 2H 2021 HANOVER, Md., May 13, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet med
Read more →PCSAProcessa Pharmaceuticals Schedules Conference Call to Discuss First Quarter Results and Provide Drug Development Update on May 13 at 5:30 p.m. EST
HANOVER, MD., May 07, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, to
Read more →PCSAProcessa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
Clinical drug pipeline is funded and targeting major milestones in 2021 HANOVER, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical con
Read more →PCSAProcessa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET
HANOVER, MD., March 22, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs,
Read more →PCSAProcessa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica
HANOVER, March 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival
Read more →PCSAProcessa Pharmaceuticals Announces Closing of a $10.2 Million Private Placement
HANOVER, MD, March 02, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is pleased to announce it has closed its previously announced private placement to institutional and accredited investors of $10.2 million. The Company sold 1,321,132 shares of the commo
Read more →PCSAProcessa Pharmaceuticals Announces $10.2 Million Strategic Financing
Strengthened Financial Position Supports Execution Through 2023 HANOVER, MD., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival an
Read more →PCSAProcessa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
HANOVER, MD., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, a
Read more →PCSAProcessa Pharmaceuticals Announces Third Quarter 2020 Results, Provides Corporate Update
HANOVER, MD., Nov. 12, 2020 (GLOBE NEWSWIRE) -- via InvestorWire -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and i
Read more →PCSAProcessa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors
HANOVER, MD, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical ne
Read more →PCSAProcessa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors HANOVER, MD
Pharmaceuticals Announces the Appointment of Khalid Islam to Its Board of Directors MD -November 5, 2020- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), ("Processa" or the "Company"), a clinical-stage biopharmaceutical company developing products to improve the survival and/or
Read more →PCSAProcessa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on Nov. 12 at 5:30 p.m. ET
HANOVER, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- via InvestorWire -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high un
Read more →PCSAProcessa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
HANOVER, Md, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical needs, is
Read more →PCSAFor More Information: Michael Floyd mfloyd@processapharma.com Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer HANOVER, Md.
FOR IMMEDIATE RELEASE For More Information: Michael Floyd mfloyd@processapharma.com Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer Md. - Oct. 13, 2020 - Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) ("Processa" or the "Company"), a clinical
Read more →PCSAProcessa Pharmaceuticals Closes $19.2 Million Public Offering
HANOVER, MD, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the survival and/or quality of life of patie
Read more →PCSAProcessa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
HANOVER, MD, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA; Nasdaq: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the survival and/or quality of
Read more →PCSAPROCESSA PHARMACEUTICALS ENTERED INTO A contingent PRECEDENT IN-LICENSING AGREEMENT WITH ELION ONCOLOGY FOR the Development of eniluracil (PCS6422) for the treatment of advanced gastrointestinal tum
PHARMACEUTICALS ENTERED INTO A contingent PRECEDENT IN-LICENSING AGREEMENT WITH ELION ONCOLOGY FOR the Development of eniluracil (PCS6422) for the treatment of advanced gastrointestinal tumors MD - August 27, 2020 - Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today
Read more →PCSAPROCESSA PHARMACEUTICALS ENTERED INTO A CONTINGENT PRECEDENT IN-LICENSING AGREEMENT WITH ELION ONCOLOGY FOR THE DEVELOPMENT OF ENILURACIL (PCS6422) FOR THE TREATMENT OF ADVANCED GASTROINTESTINAL TUMORS
HANOVER, MD, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has entered into a contingent precedent exclusive licensing agreement with Elion Oncology, Inc. to develop, manufacture and commercialize eniluracil (PCS6422) globa
Read more →PCSAPROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH YUHAN CORPORATION FOR the Development of YH12852 in Functional Gastrointestinal Disorders HANOVER, MD
PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH YUHAN CORPORATION FOR the Development of YH12852 in Functional Gastrointestinal Disorders MD - August 20, 2020 - Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has entered into a licensing agreement w
Read more →PCSAPROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH YUHAN CORPORATION FOR THE DEVELOPMENT OF YH12852 IN FUNCTIONAL GASTROINTESTINAL DISORDERS
HANOVER, MD, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has entered into a licensing agreement with Yuhan Corporation, a South Korean based company, to license in YH12852. YH12852 is a small molecule drug in development
Read more →PCSAPROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS ENTERED INTO AN AGREEMENT WITH APOSENSE, LTD TO LICENSE IN THE NEXT GENERATION IRINOTECAN DRUG
HANOVER, MD, June 01, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has signed an agreement with Aposense, LTD. to license in the patent rights and the know-how to develop and commercialize their next generation irinotecan cancer dr
Read more →PCSAPROCESSA PHARMACEUTICALS TO MOVE FORWARD WITH A PCS499 PHASE 3 TRIAL AFTER A SUCCESSFUL FDA MEETING
HANOVER, MD, March 30, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), announced the successful completion of their meeting with the U.S. Food and Drug Administration (FDA) for PCS499, its investigational product targeting the treatment of Necrobiosis Lipoi
Read more →PCSAFor More Information: Patrick Lin plin@processapharma.com 925-683-3218 PROCESSA PHARMACEUTICALS TO MOVE FORWARD WITH A PCS499 PHASE 3 TRIAL AFTER A
FOR IMMEDIATE RELEASE For More Information: Patrick Lin plin@processapharma.com 925-683-3218 PHARMACEUTICALS TO MOVE FORWARD WITH A PCS499 PHASE 3 TRIAL AFTER A SUCCESSFUL FDA MEETING MD - March 30, 2020 - Processa Pharmaceuticals, Inc. (OTCQB: PCSA), announced the success
Read more →PCSAFor More Information: Patrick Lin plin@processapharma.com 925-683-3218 PROCESSA PHARMACEUTICALS ANNOUNCES RESULTS FROM THE PHASE 2
FOR IMMEDIATE RELEASE For More Information: Patrick Lin plin@processapharma.com 925-683-3218 PHARMACEUTICALS ANNOUNCES RESULTS FROM THE PHASE 2 STUDY IN NECROBIOSIS LIPOIDICA MD - March 17, 2020 - Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmac
Read more →PCSAPROCESSA PHARMACEUTICALS ANNOUNCES RESULTS FROM THE PHASE 2 STUDY IN NECROBIOSIS LIPOIDICA
HANOVER, MD, March 17, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced the com
Read more →PCSAPROCESSA PHARMACEUTICALS ANNOUNCES FORMATION OF ITS MEDICAL AND SCIENTIFIC ADVISORY BOARD
HANOVER, MD, March 05, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA) a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced today th
Read more →PCSAFor More Information: Patrick Lin plin@processapharma.com 925-683-3218
FOR IMMEDIATE RELEASE For More Information: Patrick Lin plin@processapharma.com 925-683-3218 PHARMACEUTICALS ANNOUNCES FORMATION OF ITS MEDICAL AND SCIENTIFIC ADVISORY BOARD MD - March 5, 2020 - Processa Pharmaceuticals, Inc. (OTCQB: PCSA) a clinical stage biopharmaceutical
Read more →PCSAPROCESSA PHARMACEUTICALS PROVIDES SHAREHOLDER UPDATE
HANOVER, MD, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have a high unmet medical need condition, provides a year-end r
Read more →PCSAPROCESSA
PROCESSA PHARMACEUTICALS PROVIDES SHAREHOLDER UPDATE HANOVER, MD, February 25, 2020 (GLOBE NEWSWIRE) - Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who hav
Read more →PCSAPROCESSA PHARMACEUTICALS APPOINTS GERALDINE PANNU AS AN INDEPENDENT DIRECTOR TO THE BOARD OF DIRECTORS
HANOVER, MD, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTC: PCSA) a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need, announced today that Geraldine
Read more →PCSAPROCESSA PHARMACEUTICALS ANNOUNCES 1 FOR 7
PHARMACEUTICALS ANNOUNCES 1 FOR 7 REVERSE STOCK SPLIT OF ITS COMMON STOCK MD - December 20, 2019 - Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a
Read more →PCSAPROCESSA PHARMACEUTICALS ANNOUNCES 1 FOR 7 REVERSE STOCK SPLIT OF ITS COMMON STOCK
HANOVER, MD, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced today th
Read more →PCSAPROCESSA PHARMACEUTICALS PROVIDES AN UPDATE ON POSITIVE RESULTS FROM PCS-499 PHASE 2 TRIAL
HANOVER, MD, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, provides an update
Read more →PCSAPROCESSA PHARMACEUTICALS ANNOUNCES THE LICENSING OF AN ANTI-FIBROTIC, ANTI-INFLAMMATORY DRUG FOR THE TREATMENT OF MULTIPLE UNMET MEDICAL NEED CONDITIONS
HANOVER, MD, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced today t
Read more →PCSAPROCESSA PHARMACEUTICALS ANNOUNCES LAST PATIENT ENROLLED IN CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PCS-499 FOR THE TREATMENT OF NECROBIOSIS LIPOIDICA
HANOVER, MD, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today the
Read more →PCSAPROCESSA PHARMACEUTICALS PROVIDES A STUDY UPDATE FOR ITS ON-GOING PHASE 2 SAFETY AND TOLERABILITY CLINICAL TRIAL OF PCS-499
HANOVER, MD, July 15, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, provides an update
Read more →PCSAPROCESSA PHARMACEUTICALS ANNOUNCES TODAY THAT THEY WILL BE PRESENTING AT THE JEFFRIES 2019 GLOBAL HEALTHCARE CONFERENCE ON FRIDAY, JUNE 7TH, 2019
HANOVER, MD, May 20, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today that
Read more →PCSAPROCESSA PHARMACEUTICALS ANNOUNCES TODAY THAT THEY WILL BE PRESENTING AT THE COWEN CONFERENCE ON WEDNESDAY - MARCH 13, 2019
HANOVER, MD, March 11, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today th
Read more →PCSAPROCESSA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PCS-499 FOR THE TREATMENT OF NECROBIOSIS LIPOIDICA
HANOVER, MD, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today the
Read more →PCSAPROCESSA PHARMACEUTICALS ANNOUNCES PRESENTATION OF PCS499 DATA AT THE ANNUAL MEETING OF AMERICAN ACADEMY OF DERMATOLOGY
HANOVER, MD, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced today th
Read more →PCSAFor More Information: Patrick Lin plin@processapharma.com 925-683-3218 PROCESSA PHARMACEUTICALS ANNOUNCES PRESENTATION OF PCS499
FOR IMMEDIATE RELEASE For More Information: Patrick Lin plin@processapharma.com 925-683-3218 PHARMACEUTICALS ANNOUNCES PRESENTATION OF PCS499 DATA AT THE ANNUAL MEETING OF AMERICAN ACADEMY OF DERMATOLOGY MD - January 9, 2019 - Processa Pharmaceuticals, Inc. (OTCQB: PCS
Read more →PCSAPROCESSA PHARMACEUTICALS ANNOUNCES UP-LISTING TO OTCQB MARKET
HANOVER, MD, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today tha
Read more →PCSAFor More Information: Patrick Lin plin@processapharma.com 925-683-3218 PROCESSA PHARMACEUTICALS ANNOUNCES UP-LISTING
FOR IMMEDIATE RELEASE For More Information: Patrick Lin plin@processapharma.com 925-683-3218 PHARMACEUTICALS ANNOUNCES UP-LISTING TO OTCQB MARKET 6, 2018 - Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improv
Read more →PCSAFor More Information: Patrick Lin plin@processapharma.com 925-683-3218 PROCESSA PHARMACEUTICALS RECEIVES FDA CLEARANCE OF IND TO BEGIN PHASE 2 CLINICAL DEVELOPMENT OF PCS-499
FOR IMMEDIATE RELEASE For More Information: Patrick Lin plin@processapharma.com 925-683-3218 PHARMACEUTICALS RECEIVES FDA CLEARANCE OF IND TO BEGIN PHASE 2 CLINICAL DEVELOPMENT OF PCS-499 IN NECROBIOSIS LIPOIDICA PATIENTS MD - October 2, 2018 - Processa Pharmaceuticals
Read more →PCSAFor More Information: Patrick Lin plin@processapharma.com 925-683-3218 PROCESSA PHARMACEUTICALS RAISES $6.88
FOR IMMEDIATE RELEASE For More Information: Patrick Lin plin@processapharma.com 925-683-3218 PHARMACEUTICALS RAISES MILLION FROM PRIVATE PLACEMENTS MD - June 1, 2018 - Processa Pharmaceuticals, Inc. (OTC: PCSA) is pleased to announce it has raised a total of $6.88 mill
Read more →PCSAFor More Information: Investor Relations: Patrick Lin plin@processapharma.com 925-683-3218 PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS BEEN ASSIGNED THE LICENSE FOR THE CLINICAL STAGE COMPOUND CT
FOR IMMEDIATE RELEASE For More Information: Investor Relations: Patrick Lin plin@processapharma.com 925-683-3218 PHARMACEUTICALS ANNOUNCES THAT IT HAS BEEN ASSIGNED THE LICENSE FOR THE CLINICAL STAGE COMPOUND CTP-499 AND PLANS TO DEVELOP DRUG IN MULTIPLE UNMET MEDICAL NEED
Read more →PCSAPROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS BEEN ASSIGNED THE LICENSE FOR THE CLINICAL STAGE COMPOUND CTP-499 AND PLANS TO DEVELOP THE DRUG IN MULTIPLE UNMET MEDICAL NEED CONDITIONS
HANOVER, MD, March 21, 2018 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTC: PCSA) announced today that, as agreed in the asset purchase of Promet Therapeutics, LLC, Processa has been assigned the license for CTP-499 upon Promet’s exercising of the exclusive option to lic
Read more →PCSAProcessa Pharmaceuticals Announces Reverse Stock Split and Launches New Website HANOVER, Md.
Processa Pharmaceuticals Announces Reverse Stock Split and Launches New Website HANOVER, Md., Dec. 11, 2017 /PRNewswire/ -- Processa Pharmaceuticals, Inc. (the "Processa") (OTC PINK: PCSA), formed from the merger of Promet Therapeutics and Heatwurx Inc., is an emerging clinical
Read more →PCSACORPORATE PRESENTATION ex-99.1
CORPORATE PRESENTATION ex-99.1
Read more →PCSAINVESTOR PRESENTATION ex-99.1
INVESTOR PRESENTATION ex-99.1
Read more →PCSAFINANCIAL STATEMENTS OF PROMET THERAPEUTICS LLC ex-99.1 PROMET THERAPEUTICS, LLC FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 2016 AND THE PERIOD FROM AUGUST 31, 2015 (INCEPTION) THROUGH DECEMBER 31, 2015 TABLE O
PROMET THERAPEUTICS, LLC FINANCIAL STATEMENTS DECEMBER 31, 2016 AND THE PERIOD FROM AUGUST 31, 2015 (INCEPTION) THROUGH DECEMBER 31, 2015 Page INDEPENDENT AUDITORS REPORT 1 FINANCIAL STATEMENTS Balance Sheets 2 Statements of Operations 3 Statement of Members Equity (Defici
Read more →PCSAFINANCIAL STATEMENTS AS OF DECEMBER 31, 2015 AND DECEMBER 31, 2016 AND FOR THE PERIOD FROM AUGUST 31, 2015 (INCEPTION) THROUGH DECEMBER 31, 2015 AND THE YEAR ENDED DECEMBER 31, 2016 ex-99.1 PROMET THERAPEUTICS, LLC FINAN
PROMET THERAPEUTICS, LLC FINANCIAL STATEMENTS DECEMBER 31, 2016 AND THE PERIOD FROM AUGUST 31, 2015 (INCEPTION) THROUGH DECEMBER 31, 2015 Page INDEPENDENT AUDITORS REPORT 1 FINANCIAL STATEMENTS Balance Sheets 2 Statements of Operations 3 Statement of Members Equity (Defici
Read more →PCSAHEATWURX, INC ANNOUNCES EXECUTION OF DEFINITIVE ASSET PURCHASE AGREEMENT WITH PROMET THERAPEUTICS
HEATWURX, INC ANNOUNCES EXECUTION OF DEFINITIVE ASSET PURCHASE AGREEMENT WITH PROMET THERAPEUTICS, LLC PASADENA, Calif., October 3, 2017 /PRNewswire/ -- Heatwurx, Inc. (HUWX) ("Heatwurx") today announced that it has signed an Asset Purchase Agreement (the Acquisition ) with Prom
Read more →PCSAHEATWURX ANNOUNCES LETTER OF INTENT WITH PROMET THERAPEUTICS, LLC RELATING TO A REVERSE MERGER Heatwurx, Inc. (OTCQB: HUWX) ( Heatwurx ) (July 17,2017) today announced that it has entered into a non
HEATWURX ANNOUNCES LETTER OF INTENT WITH PROMET THERAPEUTICS, LLC RELATING TO A REVERSE MERGER Heatwurx, Inc. (OTCQB: HUWX) ( Heatwurx ) (July 17,2017) today announced that it has entered into a non-binding letter of intent ( LOI ) to engage in a reverse merger ( Merger ) with P
Read more →PCSADEBT CONVERSION AGREEMENT ex-99.2 DEBT CONVERSION AGREEMENT This Debt Conversion Agreement ( Agreement ) is made as of the 30 th day of June, 2015 by, between, and among Heatwurx, Inc., a Delaware corporation (the Compan
DEBT CONVERSION AGREEMENT This Debt Conversion Agreement ( Agreement ) is made as of the 30th day of June, 2015 by, between, and among Heatwurx, Inc., a Delaware corporation (the Company ), and JMW Fund, LLC, a Delaware limited liability company, Richland Fund, LLC, a Nevada lim
Read more →PCSASENIOR SECURED LOAN AGREEMENT ex-99.1 SENIOR SECURED LOAN AGREEMENT This Senior Secured Loan Agreement (this Agreement ), dated
SENIOR SECURED LOAN AGREEMENT This Senior Secured Loan Agreement (this Agreement ), dated February 16, 2015, is by, between and among JMW Fund, LLC, a Delaware limited liability company, Richland Fund, LLC, a Nevada limited liability company, and San Gabriel Fund, LLC, a Califor
Read more →PCSAEXCLUSIVE DISTRIBUTION AGREEMENT ex-99.1 EXCLUSIVE DISTRIBUTION AGREEMENT THIS EXCLUSIVE DISTRIBUTION AGREEMENT (the "Agreement") is made and entered into as of the 23rd day of October, 2014 by and between HEATWURX , INC
EXCLUSIVE DISTRIBUTION AGREEMENT THIS EXCLUSIVE DISTRIBUTION AGREEMENT (the "Agreement") is made and entered into as of the 23rd day of October, 2014 by and between HEATWURX , INC., a corporation organized and existing under the laws of the State of Delaware (the ''Company") and
Read more →PCSASEPARATION AND SEVERANCE AGREEMENT AND RELEASE OF CLAIMS ex-99.1 SEPARATION AND SEVERANCE AGREEMENT AND RELEASE OF CLAIMS The purpose of this Agreement is to set forth the terms and provisions of a severance agreement ag
SEPARATION AND SEVERANCE AGREEMENT AND RELEASE OF CLAIMS The purpose of this Agreement is to set forth the terms and provisions of a severance agreement agreed to between Alexander Kramer (hereinafter ''Employee") and Heatwurx, Inc. (hereinafter "Employer"), in connection with
Read more →PCSAThe Hoyt Organization, (310) 373-0103 Kent Barrett, kbarrett@hoytorg.com Katherine Carson, kcarson@hoytorg.com HEATWURX ENTERS INTO LOI TO DISTRIBUTE PATENTED ASPHALT
FOR IMMEDIATE RELEASE CONTACTS: The Hoyt Organization, (310) 373-0103 Kent Barrett, kbarrett@hoytorg.com Katherine Carson, kcarson@hoytorg.com HEATWURX ENTERS INTO LOI TO DISTRIBUTE PATENTED ASPHALT AND RESTORATION REPAIR TECHNOLOGY IN CHINA Franchisees across the nation to
Read more →PCSAThe Hoyt Organization, (310) 373-0103 Kent Barrett, kbarrett@hoytorg.com Katherine Carson, kcarson@hoytorg.com HEATWURX FRANCHISES DR. PAVE WORLDWIDE, LLC S ASPHALT R
FOR IMMEDIATE RELEASE CONTACTS: The Hoyt Organization, (310) 373-0103 Kent Barrett, kbarrett@hoytorg.com Katherine Carson, kcarson@hoytorg.com HEATWURX FRANCHISES DR. PAVE WORLDWIDE, LLC S ASPHALT REPAIR AND RESTORATION SERVICE Franchisees across the nation to be exclusive p
Read more →PCSAThe Hoyt Organization, (310) 373-0103 Kent Barrett, kbarrett@hoytorg.com Katherine Carson, kcarson@hoytorg.com HEATWURX AND DR. PAVE RELOCATE HEADQUARTERS TO SOUTHERN CALIFORNIA Los Angeles-based business strat
The Hoyt Organization, (310) 373-0103 kbarrett@hoytorg.com Katherine Carson, kcarson@hoytorg.com HEATWURX AND DR. PAVE RELOCATE HEADQUARTERS TO SOUTHERN CALIFORNIA Los Angeles-based business strategist Alexander Kramer named GARDENA, Calif. - May 27, 2014 - Heatwurx , Inc.
Read more →PCSALOAN AGREEMENT ex-99.1 LOAN AGREEMENT This Loan Agreement (the Agreement ) dated
This Loan Agreement (the Agreement ) dated January 6, 2014, is by and between the lenders executing the Signature Page of this Agreement (collectively, the Lenders ) on the one hand, and Heatwurx Inc., a Delaware corporation ( Borrower ), on the other hand. WHEREAS, Borrower is
Read more →PCSAHeatwurx Granted Additional Patent from the U.S. Patent and Trademark Office GREENWOOD VILLAGE, Colo.
Heatwurx Granted Additional Patent from the U.S. Patent and Trademark Office GREENWOOD VILLAGE, Colo. -- Oct. 28, 2013 -- Heatwurx, Inc. (OTCQB: HUWX), an eco-friendly asphalt preservation and repair equipment company, announced today that the company was granted a new patent fr
Read more →PCSAHeatwurx Equipment Granted Patent from the U.S. Patent and Trademark Office Greenwood Village, CO.
Heatwurx Equipment Granted Patent from the U.S. Patent and Trademark Office Greenwood Village, CO., Oct. 21, 2013 /Businesss Wire/ --Heatwurx, Inc. (HUWX), an eco-friendly asphalt preservation and repair equipment company, announced today that it has been granted a new patent fr
Read more →PCSAHeatwurx Announces Management Transition Greenwood Village, CO
Heatwurx Announces Management Transition Greenwood Village, CO, - Sep. 27, 2013 Heatwurx, Inc announced today that President and Chief Executive Officer Stephen Garland will transition from his position later this year, upon the completion of the process to choose his successor.
Read more →PCSAPotholes Beware! Lake Elsinore Bringing an Innovative Repair Weapon to Battle The City of Lake Elsinore will be the FIRST California entity to use a promising, new in-place asphalt repair
Potholes Beware! Lake Elsinore Bringing an Innovative Repair Weapon to Battle The City of Lake Elsinore will be the FIRST California entity to use a promising, new in-place asphalt repair technology designed to repair local roads for good. LAKE ELSINORE, CA, July 10, 2013 Few
Read more →PCSAPRESS RELEASE ex99.1
HEATWURX EQUIPMENT RECOMMENDED FOR REPAIRS ON MILITARY AIRFIELD PAVEMENTS GREENWOOD VILLAGE, Colo., July 9, 2013 HEATWURX, Inc., an asphalt preservation and repair equipment manufacturer, announced today that the U.S. Army Corps of Engineers has completed its evaluation of equi
Read more →Competitive Position
How PCSA ranks across every disease it competes inCompetitive Position is a premium feature
See how PCSA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial